Seven charter schools will close after this school year, according to the Texas Education Agency, affecting about 2,000 ...

Incyte (INCY) shares soared 5.5% in the last trading session to close at $102.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Incyte (INCY) has been quietly outperforming the broader biotech space this year, with the stock up about 46% over the past year and more than 40% year to date, drawing fresh attention. See our latest ...

Fintel reports that on December 8, 2025, Mizuho upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to Outperform. Analyst Price Forecast Suggests 6.11% Downside As of December 6, 2025, the ...

We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...

Greetings, and welcome to the Incyte Third Quarter 2025 Earnings Conference Call webcast [Operator Instructions]. As a reminder, this conference is being recorded. It's now my pleasure to turn the ...

The Health Care Select Sector SPDR® Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12.12% in the S&P 500 index, advanced 1.80% in Q3, falling short of the S&P ...

Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 ...

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Incyte (INCY – Research Report), with a price target of $77.00. The company’s shares closed last Friday at ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...